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ABSTRACT
Objective: The present study describes the stability indicating reversed-phase high-performance liquid chromatography (RP-HPLC) method for 
simultaneous estimation of 5-fluorouracil and tegafur in pharmaceutical dosage forms.
Method: 5-fluorouracil and tegafur the propose RP-HPLC method were developed by using Shimadzu Prominence-i LC-2030 HPLC system equipped 
with UV detector and chromatographic separation was carried on shim-pack gist c18 (250 × 4.6 mm, 5 µ) column at a flow rate of 1 ml/min and the 
run time was 10 min. The mobile phase consisted of methanol and water in the ratio of 50:50% v/v and elements were scanned using a UV detector 
at 271 nm.
Result: The retention time of 5-fluorouracil and tegafur was found to be 2.74 and 3.66 min, respectively. A linearity response was observed in the 
concentration range of 13.4 µg/ml–31.3 µg/ml for 5-fluorouracil and 6 µg/ml–14 µg/ml for tegafur, respectively. Limit of detection and limit of 
quantification of 5-fluorouracil were 10.97 µg/ml and 33.26 µg/ml and for tegafur are 4.89 µg/ml and 14.83 µg/ml, respectively.
Conclusion: The stability indicating that the method was developed by subjecting drugs to stress conditions such as acid and base hydrolysis, 
oxidation, photo and thermal degradation, and degraded products formed were resolved successfully from samples.
Keywords: 5-Fluorouracil, Tegafur, Reversed-phase high-performance liquid chromatography, Degradation and validation.
INTRODUCTION
5-Fluorouracil (Fig. 1) (5-fluoro-pyrimidine-2,4-dione) has been widely 
used in the chemotherapy of a variety of human carcinomas, including 
the head, neck, and gastrointestinal tract and breast using various 
schedules [1]. However, administration of the compound often caused 
severe gastrointestinal toxicity and myelosuppression. To overcome the 
toxicity, many derivatives and related compound have been synthesized [4].
Tegafur (Fig. 2) [5-fluoro-1-(oxolan-2-yl) pyrimidine-2,4-dione] a 
2-tetrahydrofuranyl derivative of 5-fluorouracil has been shown 
to have a broad spectrum of antitumor activity when administered 
intravenously or orally [1]. It acts as a prodrug of 5-fluorouracil and 
produces comparatively little myelosuppression [2,3].
Literature survey reveals HPLC for estimation 5-fluorouracil and 
tegafur is not available for pharmaceutical dosage form.
METHODS
5-fluorouracil and tegafur standard were provided by Yarrow Chem. 
Products, Dombivali, Mumbai, Maharashtra, India. Commercial tablet 
dosage form tegafur (5-fluorouracil 224 mg and Tegafur 100 mg) 
was purchased from local markets. The HPLC grade methanol and 
water were purchased from Thomas Fisher scientific Pvt. Ltd., Powai, 
Mumbai, Maharashtra, India. Hydrochloric acid, sodium hydroxide, and 
hydrogen peroxide were purchased from S.D. Fine chemicals.
HPLC instrument
The chromatographic separation was carried out by Shimadzu 
Prominence-i LC-2030 HPLC system equipped with UV detector and 
autosampler. The lab solution software was used for signal monitoring 
and processing, UV chamber has been used for photolytic degradation. 
Hot air oven was used for thermal degradation.
Chromatographic conditions
The chromatographic separation of analytes was carried out using 
Shimadzu reversed-phase high-performance liquid chromatography 
(RP-HPLC) system with Shim-pack GIST C18 (250 × 4.6 mm) column. 
The mobile phase consists of water and methanol in the ratio 50:50 
%v/v, and column temperature was maintained at 30°C the analytes 
were detected at 271 nm using UV detector. The runtime was set at 
10 min at a flow rate of 1 ml/min.
Preparation of standard stock solution
Standard stock solution of 5-fluorouracil and tegafur was prepared 
separately by dissolving 22.4 mg of 5-fluorouracil and 10mg of 
tegafur in 100 ml of volumetric flask with water:methanol (50:50) as 
diluents and sonicated for 10 min. From the above solution, 1 ml of 
5-fluorouracil and 1 ml of tegafur were transferred separately to 10 ml 
volumetric flask, made up the volume to get 24 µg/ml and 10 µg/ml of 
stock solution of 5-fluorouracil and tegafur respectively.
Preparation of sample solution
Ten tablets (Tegafur capsule; 224 mg 5-fluorouracil and 10 mg tegafur) 
were weighed and the average weight of each tablet was calculated; 
then the weight equivalent to 10 tablets was transferred into 100 ml 
volumetric flask; 50 ml of diluents were added and sonicated for 
30 min; further the volume made up with diluents and filtered. From 
the filtered solution, 1 ml was pipette out into 10 ml volumetric flask 
and sonicated for 10 min, and volume made up to 10 ml with diluents.
Forced degradation studies
Forced degradation studies were carried out in the presence of acid, 
alkali, H2O2, and heat. With the sample bearing concentration 22.4 µg/ml 
and 10 µg/ml of 5-fluorouracil and tegafur, respectively, these studies 
help to know the inherent stability characteristic of the active molecule 
in drug product and possible degradation products [6,7].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.27858
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Acid degradation
Acidic degradation was carried out by adding 5 ml of 1N HCl and after 
60 min neutralizing the mixture by adding 5 ml of 1N NaOH.
Alkali degradation
Alkali degradation was carried out by adding 5 ml of 1N NaOH and after 
60 min neutralizing the mixture by adding 5 ml of 1N HCl.
Oxidative degradation
Oxidative degradation was performed by exposing the drug to 5 ml of 
10% (v/v) H2O2 for 60 min.
Photolytic degradation
Photolytic degradation was carried out by exposing the drug content to 
UV light inside a UV chamber for 1d.
Thermal degradation
Thermal degradation was performed by placing the drug in an oven at 
105°C for 24 h to study dry heat degradation.
Statistical analysis
To evaluate the contribution of each factor with different levels of 




A number of trials were conducted with different columns, with various 
combination mobile phases to develop a suitable RP-HPLC method for 
estimation of 5-fluorouracil and tegafur in tablet dosage form. Then, 
finally a typical chromatogram was obtained with water and methanol in 
the ratio 50:50% v/v. The chromatographic separation was performed 
on SHIM-PACK C-18 (250 × 4.6 mm, 5 µ) column on injecting 20 µL, and 
the analysts were detected with UV detector at 271 nm. The retention 
time of 5-fluorouracil and tegafur was found to be 2.7 min and 3.6 min, 
respectively. The force degradation study was also carried out using the 
developed method. The optimized conditions were given in Table 1.
Method validation
The validation was performed with an above developed RP-HPLC 
method for simultaneous estimation of 5-fluorouracil and tegafur 
according to ICH guidelines. Various parameters were evaluated such 
as system suitability, precision, accuracy, linearity, robustness, limit of 
detection (LOD), and limit of quantification (LOQ).
System suitability
System suitability was performed to verify the acceptability of the 
resolution and repeatability of the system. System suitability was 
Fig. 1: 5-fluorouracil
Table 1: Optimized chromatographic conditions
S. No Parameter Optimized conditions
1 Column SHIM-PACK C-18 (250×4.6 mm, 5 µ) 
column
2 Mobile phase Methanol and water 50:50% v: v
3 Flow rate 1 ml/min
4 Wavelength UV detector 271 nm
5 Injection volume 20 µL
6 Temperature 30°C
7 Retention time 5-fluorouracil 2.74 min and tegafur 
3.66 min
Table 2: System suitability parameters
Sr. No Parameters 5-fluorouracil Tegafur
1 Retention time 2.74 3.66
2 USP plate count 3765 4652
3 USP tailing 1.21 1.16
Fig. 2: Tegafur
Fig. 3: Chromatogram of standard 5-fluorouracil and tegafur
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performed by injecting six replicate injections of the standard solution 
(100%) and parameters such as peak area, USP tailing, theoretical plates, 
retention time, and peak asymmetry were evaluated. The percentage 
RSD was determined and reported within limits (Table 2 and Fig. 3).
Accuracy
The accuracy of the proposed method was evaluated by calculating 
the recovery studies of the test drug at three different concentration 
levels (80%, 100%, and 120%) by the standard addition method. 
A known amount of 5-fluorouracil and tegafur was added to the pre 
quantified sample solution, and three replicates of each concentration 
were injected into developing chromatographic conditions. The mean 
percentage recovery of 5-fluorouracil and tegafur was varied between 
99.5 and 100.4% indicating that the developed method was found to be 
accurate (Table 3).
Precision
The precision of an analytical procedure may be defined as the 
closeness of agreement between a series of measurements obtained 
from multiple sampling of the same homogeneous sample under the 
prescribed conditions. The method precision and system precision 
studies were carried out by injecting six replicates of both standard 
and test solutions with the same concentration. The percentage RSD 
was calculated from the chromatograms and the results obtained were 
within the limits of 2%, and the proposed method was found to be 
precise (Table 4).
Linearity
The linearity of the method was determined at different concentration 
levels ranging from 13.44 μg/ml to 31.36 μg/ml of 5-fluorouracil 
and from 6 μg/ml to 14 μg/ml of tegafur. All the concentrations 
were prepared and injected into the system. The linearity curve was 
constructed by plotting peak area versus concentration of the analyte. 
From the results obtained that the proposed method was found to be 
linear. The regression coefficient was found to be 0.998 and 0.998 for 
5-fluorouracil and tegafur, respectively (Figs. 4 and 5).
LOD and LOQ
In the present study, the LOD and LOQ 5-fluorouracil and tegafur were 
evaluated based on the standard calibration curve method. LOD is 
performed to know the lowest concentration level of the analysts that 
give a measurable response. LOD and LOQ for 5-fluorouracil are 10.97 
μg/ml and 33.26 μg/ml and for tegafur are 4.89 μg/ml and 14.83 μg/ml, 
respectively.
Robustness
Robustness of the proposed method has been evaluated by small 
deliberate changes in the system parameters such as flow rate, 
Table 3: Percentage recovery results of 5-fluorouracil and tegafur
S. No Spiked (%) Percentage recovery Mean percentage recovery % RSD
5-fluorouracil Tegafur 5-fluorouracil Tegafur
1 80 99.56 99.67 99.66 0.05 0.05
99.61 99.71
99.67 99.78
2 100 99.86 99.84 99.90 0.06 0.04
99.92 99.92
99.98 99.89
3 120 99.98 100.26 100.35 0.49 0.24
100.46 99.98
100.97 100.46
Fig. 4: Linearity graph of 5-fluorouracil
Fig. 5: Linearity graph of tegafur
Fig. 6: Chromatograph of untreated capsule (sample)
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wavelength, and temperature. It was found that none of the above 
parameters caused an alteration in the peak area, retention time, and 
USP tailing by small changes such as ±0.2 ml change in flow rate, ±2 nm 
wavelength, and ±2°C change in temperature. The percentage RSD 
was found to be within limits, and the method was found to be robust 
(Table 5).
Assay of marketed formulation
Analysis of the marketed formulation (tegafur capsule: 5-fluorouracil 
is 224 mg and tegafur is 100 mg) was purchased from the local 
pharma market. 10 capsules weighed and average weight were 
calculated; weight equivalent to 1capsules was transferred into 
100 ml volumetric flask, 50 ml of diluents was added and sonicated 
for 30 min, and further volume was made up with diluents and 
filtered. From filtered solution, 1 ml was a pipette out into 100 ml 
volumetric flask and made up to 100 ml with diluents. From the 
resulting solution, 20 µL was injected into HPLC system, and 
peak areas were recorded. The percentage assay of the marketed 
formulation was found to be 98.7 for 5-fluorouracil and 98.6 for 
tegafur (Table 6).
Fig. 8: Chromatograph of base degradation
Fig. 9: Chromatograph of ultraviolet degradation
Fig. 7: Chromatograph of acid degradation
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Forced degradation studies (Figs. 6-11)
ICH degradation was attempted to various stress conditions such 
as acid hydrolysis (using 1N HCl), base hydrolysis (using 1N NaOH), 
oxidative hydrolysis (using 5% H2O2), thermal degradation (heated at 
100°C for 24 h), and photolytic degradation (using UV light inside a 
UV chamber for 48 h). The results of stress studies were shown in 
Table 7.
CONCLUSION
In the present study, a method has been developed using RP-HPLC 
and validated for simultaneous estimation with stability indication of 
5-fluorouracil and tegafur in tablet dosage form. The validated method 
was successfully used for stress testing, analysis of 5-fluorouracil and 
tegafur. The proposed method was proved selective, accurate, precise, 
and rapid and it can be used for the routine analysis of 5-fluorouracil 
and tegafur in the formulation.
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Fig. 10: Chromatograph of thermal degradation
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